These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15349006)

  • 1. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.
    Papakostas GI; Petersen T; Denninger JW; Tossani E; Pava JA; Alpert JE; Nierenberg AA; Fava M
    J Clin Psychopharmacol; 2004 Oct; 24(5):507-11. PubMed ID: 15349006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.
    Fava M; Alpert J; Nierenberg A; Lagomasino I; Sonawalla S; Tedlow J; Worthington J; Baer L; Rosenbaum JF
    J Clin Psychopharmacol; 2002 Aug; 22(4):379-87. PubMed ID: 12172337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder.
    Papakostas GI; Petersen T; Denninger JW; Montoya HD; Nierenberg AA; Alpert JE; Fava M
    Ann Clin Psychiatry; 2003; 15(3-4):187-92. PubMed ID: 14971864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
    Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
    Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M
    J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity among outpatients with major depressive disorder.
    Papakostas GI; Petersen T; Iosifescu DV; Burns AM; Nierenberg AA; Alpert JE; Rosenbaum JF; Fava M
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):59-63. PubMed ID: 15361263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
    Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
    Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
    Trivedi MH; Thase ME; Osuntokun O; Henley DB; Case M; Watson SB; Campbell GM; Corya SA
    J Clin Psychiatry; 2009 Mar; 70(3):387-96. PubMed ID: 19284928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
    Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of medical comorbidity on acute treatment in major depressive disorder.
    Iosifescu DV; Nierenberg AA; Alpert JE; Smith M; Bitran S; Dording C; Fava M
    Am J Psychiatry; 2003 Dec; 160(12):2122-7. PubMed ID: 14638581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
    Gelenberg AJ; Dunner DL; Rothschild AJ; Pedersen R; Dorries KM; Ninan PT
    J Nerv Ment Dis; 2013 Apr; 201(4):266-73. PubMed ID: 23538970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder.
    Lin CH; Chen CC; Wong J; McIntyre RS
    J Affect Disord; 2014 Jun; 161():123-6. PubMed ID: 24751319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Problem-solving ability and comorbid personality disorders in depressed outpatients.
    Harley R; Petersen T; Scalia M; Papakostas GI; Farabaugh A; Fava M
    Depress Anxiety; 2006; 23(8):496-501. PubMed ID: 16845662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity among depressed outpatients considered to be in remission.
    Zimmerman M; Posternak MA; Chelminski I
    Compr Psychiatry; 2007; 48(2):113-7. PubMed ID: 17292700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.
    Abolfazli R; Hosseini M; Ghanizadeh A; Ghaleiha A; Tabrizi M; Raznahan M; Golalizadeh M; Akhondzadeh S
    Depress Anxiety; 2011 Apr; 28(4):297-302. PubMed ID: 21456039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.
    Nierenberg AA; Husain MM; Trivedi MH; Fava M; Warden D; Wisniewski SR; Miyahara S; Rush AJ
    Psychol Med; 2010 Jan; 40(1):41-50. PubMed ID: 19460188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
    J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind pilot trial of desipramine versus fluoxetine in panic patients.
    Bystritsky A; Rosen RM; Murphy KJ; Bohn P; Keys SA; Vapnik T
    Anxiety; 1994-1995; 1(6):287-90. PubMed ID: 9160589
    [No Abstract]   [Full Text] [Related]  

  • 19. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
    Cassano P; Soares CN; Cohen LS; Lyster AK; Fava M
    Arch Womens Ment Health; 2004 Jul; 7(3):167-71. PubMed ID: 15241662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination.
    Hirschfeld RM; Dunner DL; Keitner G; Klein DN; Koran LM; Kornstein SG; Markowitz JC; Miller I; Nemeroff CB; Ninan PT; Rush AJ; Schatzberg AF; Thase ME; Trivedi MH; Borian FE; Crits-Christoph P; Keller MB
    Biol Psychiatry; 2002 Jan; 51(2):123-33. PubMed ID: 11822991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.